日本内科学会

The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence 査読有り 国際誌

Tanaka Ichidai, Furukawa Taiki, Morise Masahiro

CANCER CELL INTERNATIONAL   21 巻 ( 1 ) 頁： 454   2021年8月

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma. 査読有り 国際誌

Nakagawa K, Kijima T, Okada M, Morise M, Kato M, Hirano K, Fujimoto N, Takenoyama M, Yokouchi H, Ohe Y, Hida T, Aoe K, Kishimoto T, Hirokawa M, Matsuki H, Kaneko Y, Yamada T, Morimoto C, Takeda M

JTO clinical and research reports   2 巻 ( 6 ) 頁： 100178   2021年6月

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With <i>EGFR</i> Mutations. 査読有り 国際誌

Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y

JTO clinical and research reports   2 巻 ( 1 ) 頁： 100107   2021年1月

新型コロナウイルス感染症に対するSARS-CoV-2抗体検査試薬の検討―抗原種の違いによる特性と抗体アイソタイプの関連― 査読有り 国際誌

金 貞姫, 菊地 良介, 鈴木 敦夫, 度會 理佳, 横山 覚, 森瀬 昌宏, 八木 哲也, 松下 正

医学検査   69 巻 ( 4 ) 頁： 554 - 561   2020年10月

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC 査読有り 国際共著 国際誌

Herbst Roy S., Giaccone Giuseppe, de Marinis Filippo, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos H., Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Zou Wei, Sandler Alan, Enquist Ida, Komatsubara Kimberly, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, McCleland Mark, Mocci Simonetta, Jassem Jacek, Spigel David R.

NEW ENGLAND JOURNAL OF MEDICINE   383 巻 ( 14 ) 頁： 1328 - 1339   2020年10月

Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy 査読有り 国際誌

Sugawara Shunichi, Inui Naoki, Kanehara Masashi, Morise Masahiro, Yoshimori Kozo, Kumagai Toru, Fukui Tomoya, Minato Koichi, Iwashima Akira, Takeda Yuichiro, Kubota Kaoru, Saeki Toshiaki, Tamura Tomohide

CANCER   125 巻 ( 22 ) 頁： 4076 - 4083   2019年11月

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV 査読有り 国際誌

Akamatsu Hiroaki, Ninomiya Kiichiro, Kenmotsu Hirotsugu, Morise Masahiro, Daga Haruko, Goto Yasushi, Kozuki Toshiyuki, Miura Satoru, Sasaki Takaaki, Tamiya Akihiro, Teraoka Shunsuke, Tsubata Yukari, Yoshioka Hiroshige, Hattori Yoshihiro, Imamura Chiyo K., Katsuya Yuki, Matsui Reiko, Minegishi Yuji, Mizugaki Hidenori, Nosaki Kaname, Okuma Yusuke, Sakamoto Setsuko, Sone Takashi, Tanaka Kentaro, Umemura Shigeki, Yamanaka Takeharu, Amano Shinsuke, Hasegawa Kazuo, Morita Satoshi, Nakajima Kazuko, Maemondo Makoto, Seto Takashi, Yamamoto Nobuyuki

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   24 巻 ( 7 ) 頁： 731 - 770   2019年7月

12）高齢者肺癌の臨床 国際誌

長谷川 好規, 森瀬 昌宏

日本内科学会雑誌   106 巻 ( 9 ) 頁： 1986 - 1990   2017年9月

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis 査読有り 国際誌

Gen Soei, Tanaka Ichidai, Morise Masahiro, Koyama Junji, Kodama Yuta, Matsui Akira, Miyazawa Ayako, Hase Tetsunari, Hibino Yoshitaka, Yokoyama Toshihiko, Kimura Tomoki, Yoshida Norio, Sato Mitsuo, Hashimoto Naozumi

BMC CANCER   22 巻 ( 1 ) 頁： 654   2022年6月

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer 査読有り 国際誌

Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Kim Deoksu, Shimoyama Yoshie, Hashimoto Naozumi

INTERNAL MEDICINE   61 巻 ( 5 ) 頁： 703 - 708   2022年5月

Resistance to mutant KRASV12-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line 査読有り 国際共著

Muraki N, Yamada M, Doki H, Nakai R, Komeda K, Goto D, Kawabe N, Matsuoka K, Matsushima M, Kawabe T, Tanaka I, Morise M, Shay JW, Minna JD, Sato M.

Exp Cell Res   414 巻 ( 1 ) 頁： 113053   2022年5月

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE) 査読有り 国際誌

Hata Akito, Shiraishi Yoshimasa, Inui Naoki, Okada Morihito, Morise Masahiro, Akiyoshi Kohei, Takeda Masayuki, Watanabe Yasutaka, Sugawara Shunichi, Shinagawa Naofumi, Kubota Kaoru, Saeki Toshiaki, Tamura Tomohide

ONCOLOGY AND THERAPY     2022年3月

INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance 査読有り 国際共著 国際誌

Smit Egbert F., Dooms Christophe, Raskin Jo, Nadal Ernest, Tho Lye M., Le Xiuning, Mazieres Julien, Hin How S., Morise Masahire, Zhu Viola W., Tan Daniel, Holmberg Kristina H., Ellers-Lenz Barbara, Adrian Svenja, Brutlach Sabine, Schumacher Karl M., Karachaliou Niki, Wu Yi-Long

FUTURE ONCOLOGY   18 巻 ( 9 ) 頁： 1039 - 1054   2022年3月

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations 査読有り 国際誌

Tanaka Ichidai, Morise Masahiro

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   23 巻 ( 1 )   2022年1月

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer 査読有り 国際誌

Yasuda Hiroyuki, Ichihara Eiki, Sakakibara-Konishi Jun, Zenke Yoshitaka, Takeuchi Shinji, Morise Masahiro, Hotta Katsuyuki, Sato Mineyoshi, Matsumoto Shingo, Tanimoto Azusa, Matsuzawa Reiko, Kiura Katuyuki, Takashima Yuta, Yano Seiji, Koyama Junji, Fukushima Takahiro, Hamamoto Junko, Terai Hideki, Ikemura Shinnosuke, Takemura Ryo, Goto Koichi, Soejima Kenzo

LUNG CANCER   162 巻   頁： 140 - 146   2021年12月

Oxytocin receptor is a promising therapeutic target of malignant mesothelioma 査読有り 国際誌

Kodama Yuta, Tanaka Ichidai, Sato Tatsuhiro, Hori Kazumi, Gen Soei, Morise Masahiro, Matsubara Daisuke, Sato Mitsuo, Sekido Yoshitaka, Hashimoto Naozumi

CANCER SCIENCE   112 巻 ( 9 ) 頁： 3520 - 3532   2021年9月

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 査読有り 国際誌

Ito K., Morise M., Wakuda K., Hataji O., Shimokawaji T., Takahashi K., Furuya N., Takeyama Y., Goto Y., Abe T., Kato T., Ozone S., Ikeda S., Kogure Y., Yokoyama T., Kimura M., Yoshioka H., Murotani K., Kondo M., Saka H.

ESMO OPEN   6 巻 ( 3 )   2021年6月

A phase III, randomized, double-blind, multicenter, active control study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC): CONSOLE. 査読有り 国際誌

Shiraishi, Y; Hata, A; Inui, N; Okada, M; Morise, M; Akiyoshi, K; Takeda, M; Watanabe, Y; Sugawara, S; Shinagawa, N; Kubota, K; Saeki, T; Tamura, T

JOURNAL OF CLINICAL ONCOLOGY   39 巻 ( 15 )   2021年5月

IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC 査読有り 国際共著 国際誌

Herbst R., De Marinis F., Giaccone G., Vergnenegre A., Barrios C., Morise M., Felip E., Oprean C., Kim Y., Andric Z., Mocci S., Enquist I., Komatsubara K., Mccleland M., Deng Y., Kuriki H., Villalobos M., Phan S., Spigel D., Jassem J.

JOURNAL OF THORACIC ONCOLOGY   16 巻 ( 3 ) 頁： S224 - S225   2021年3月

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study 査読有り 国際共著 国際誌

Seto Takashi, Hayashi Hidetoshi, Satouchi Miyako, Goto Yasushi, Niho Seiji, Nogami Naoyuki, Hida Toyoaki, Takahashi Toshiaki, Sakakibara-Konishi Jun, Morise Masahiro, Nagasawa Takashi, Suzuki Mie, Ohkura Masayuki, Fukuhara Kei, Thurm Holger, Peltz Gerson, Nishio Makoto

CANCER SCIENCE   111 巻 ( 10 ) 頁： 3726 - 3738   2020年10月

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study 査読有り 国際誌

Nakano Takashi, Kuribayashi Kozo, Kondo Masashi, Morise Masahiro, Tada Yuji, Hirano Katsuya, Hayashi Morihiko, Tanaka Misa, Hirabayashi Masataka

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY     2020年9月

Clinical burden of immune checkpoint inhibitor-induced pneumonitis 査読有り 国際誌

Sakamoto Koji, Fukihara Jun, Morise Masahiro, Hashimoto Naozumi

RESPIRATORY INVESTIGATION   58 巻 ( 5 ) 頁： 305 - 319   2020年9月

Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer 査読有り 国際誌

Matsui Akira, Morise Masahiro, Tanaka Ichidai, Ozone Sachiko, Matsuzawa Reiko, Koyama Junji, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

CANCER INVESTIGATION   38 巻 ( 7 ) 頁： 424 - 430   2020年8月

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation 査読有り 国際誌

Tanaka Ichidai, Morise Masahiro, Miyazawa Ayako, Kodama Yuta, Tamiya Yutaro, Gen Soei, Matsui Akira, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

CLINICAL LUNG CANCER   21 巻 ( 3 ) 頁： 273 - +   2020年5月

Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With NoneSmall-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors" 査読有り 国際誌

Fukihara Jun, Sakamoto Koji, Koyama Junji, Ito Takayasu, Iwano Shingo, Morise Masahiro, Ogawa Masahiro, Kondoh Yasuhiro, Kimura Tomoki, Hashimoto Naozumi, Hasegawa Yoshinori

CLINICAL LUNG CANCER   21 巻 ( 3 ) 頁： E205 - E205   2020年5月

UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer 査読有り 国際誌

Goto Daiki, Komeda Kazuki, Uwatoko Natsuki, Nakashima Moeka, Koike Mayu, Kawai Kaho, Kodama Yuta, Miyazawa Ayako, Tanaka Ichidai, Hase Tetsunari, Morise Masahiro, Hasegawa Yoshinori, Kawabe Tsutomu, Sato Mitsuo

CANCER INVESTIGATION   38 巻 ( 4 ) 頁： 240 - 249   2020年4月

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study 査読有り 国際誌

Shimokawa Mototsugu, Nosaki Kaname, Seto Takashi, Ohashi Kadoaki, Morise Masahiro, Horinouchi Hidehito, Sakakibara Jun, Murakami Haruyasu, Yano Seiji, Satouchi Miyako, Matsumoto Shingo, Goto Koichi, Yoh Kiyotaka

TRIALS   21 巻 ( 1 )   2020年3月

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study 査読有り 国際誌

Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

BRITISH JOURNAL OF CANCER   122 巻 ( 6 ) 頁： 771 - 777   2020年3月

Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer 査読有り 国際誌

Shimizu Takahiro, Okachi Shotaro, Imai Naoyuki, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

NAGOYA JOURNAL OF MEDICAL SCIENCE   82 巻 ( 1 ) 頁： 69 - 77   2020年2月

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer 査読有り 国際誌

Nakagawa Kazuhiko, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Azuma Koichi, Kim Young Hak, Seto Takashi, Takiguchi Yuichi, Nishio Makoto, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Koyama Ryo, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Hayashi Morihiko, Hasegawa Wakako, Tamura Tomohide

LUNG CANCER   139 巻   頁： 195 - 199   2020年1月

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study 査読有り 国際誌

Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Okuji Takayuki, Ito Masaaki, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Hibi Hideharu, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

JOURNAL FOR IMMUNOTHERAPY OF CANCER   8 巻 ( 2 )   2020年

Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors 査読有り 国際誌

Fukihara Jun, Sakamoto Koji, Koyama Junji, Ito Takayasu, Iwano Shingo, Morise Masahiro, Ogawa Masahiro, Kondoh Yasuhiro, Kimura Tomoki, Hashimoto Naozumi, Hasegawa Yoshinori

CLINICAL LUNG CANCER   20 巻 ( 6 ) 頁： 442 - +   2019年11月

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations 査読有り 国際誌

Tanaka Ichidai, Morise Masahiro, Kodama Yuta, Matsui Akira, Ozawa Naoya, Ozone Sachiko, Goto Daiki, Miyazawa Ayako, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

LUNG CANCER   127 巻   頁： 169 - 171   2019年1月

eIF2 beta, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer 査読有り 国際共著 国際誌

Tanaka Ichidai, Sato Mitsuo, Kato Toshio, Goto Daiki, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE   109 巻 ( 6 ) 頁： 1843 - 1852   2018年6月

Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer

Okachi Shotaro, Imaizumi Kazuyoshi, Imai Naoyuki, Shimizu Takahiro, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

EUROPEAN GERIATRIC MEDICINE   9 巻 ( 2 ) 頁： 255-262   2018年4月

Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study 査読有り 国際誌

Shintani Yasushi, Hasegawa Seiki, Takuwa Teruhisa, Aoe Keisuke, Kato Katsuya, Fujimoto Nobukazu, Hida Yasuhiro, Morise Masahiro, Moriya Yasumitsu, Morohoshi Takao, Okumura Meinoshin, Yoshino Ichiro

JOURNAL OF THORACIC DISEASE   10 巻 ( 3 ) 頁： 1968 - 1971   2018年3月

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study 査読有り 国際誌

Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

JOURNAL OF THE ENDOCRINE SOCIETY   2 巻 ( 3 ) 頁： 241 - 251   2018年3月

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting 査読有り 国際誌

Tanaka Ichidai, Kawada Kenji, Morise Masahiro, Hase Tetsunari, Hayashi Hiroaki, Sokai Akihiko, Fukatsu Asuki, Kondo Masashi, Nomura Fumio, Hasegawa Yoshinori

CANCER CHEMOTHERAPY AND PHARMACOLOGY   81 巻 ( 2 ) 頁： 339 - 345   2018年2月

An <i>EGFR</i>-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib 査読有り 国際誌

Sato Mitsuo, Matsui Akira, Shimoyama Yoshie, Omote Norihito, Morise Masahiro, Hase Tetsunari, Tanaka Ichidai, Suzuki Kojiro, Hasegawa Yoshinori

Internal Medicine   57 巻 ( 23 ) 頁： 3429 - 3432   2018年

Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer 査読有り 国際共著 国際誌

Kakumu Tomohiko, Sato Mitsuo, Goto Daiki, Kato Toshio, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Fukui Takayuki, Yokoi Kohei, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE   108 巻 ( 4 ) 頁： 732 - 743   2017年4月

Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy. 査読有り

Omote N, Hashimoto N, Morise M, Sakamoto K, Miyazaki S, Ando A, Nakahara Y, Hasegawa Y.

Int J Chron Obstruct Pulmon Dis.   11 巻 ( 12 ) 頁： 3541-3547   2017年

Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy 査読有り 国際誌

Omote Norihito, Hashimoto Naozumi, Morise Masahiro, Sakamoto Koji, Miyazaki Shinichi, Ando Akira, Nakahara Yoshio, Hasegawa Yoshinori

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE   12 巻   頁： 3541 - 3547   2017年

Factors Affecting the Diagnostic Yield of Transbronchial Biopsy Using Endobronchial Ultrasonography with a Guide Sheath in Peripheral Lung Cancer. 査読有り

Okachi S, Imai N, Imaizumi K, Iwano S, Ando M, Hase T, Aso H, Morise M, Wakahara K, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y

Intern Med   55 巻 ( 13 ) 頁： 1705-12   2016年

The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung 査読有り

Sekihara K, Hishida T, Ikemura S, Saruwatari K, Morise M, Kuwata T, Fujii S, Kojima M, Ochiai A, Funai K, Aokage K, Yoshida J, Tsuboi M, Ishii G

J Cancer Res Clin Oncol   142 巻 ( 5 ) 頁： 905-912   2016年

Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? 査読有り

Kato T, Morise M (equal first author), Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y

Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?   142 巻 ( 7 ) 頁： 1629-40   2016年

Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung 査読有り

Udagawa H, Ishii G, Morise M, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A, Ohe Y

J Cancer Res Clin Oncol   141 巻 ( 8 ) 頁： 1417-25.   2015年

Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy

Koriyama H, Ishii G, Yoh K, Neri S, Morise M, Umemura S, Matsumoto S, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A

J Cancer Res Clin Oncol   141 巻 ( 7 ) 頁： 1163-70   2015年

Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma 査読有り

Aramaki N, Ishii G, Yamada E, Morise M, Aokage K, Kojima M, Hishida T, Yoshida J, Ikeda N, Tsuboi M, Ochiai A

  142 巻 ( 1 ) 頁： 37-46   2015年

Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung 査読有り

Morise M, Hishida T, Takahashi A, Yoshida J, Ohe Y, Nagai K, Ishii G

Journal of cancer research and clinical oncology     頁： 2015 May 12. [Epub ahead of print]   2015年

環境因子と呼吸器悪性腫瘍 招待有り

森瀬昌宏, 長谷川好規

呼吸と循環   62 巻 ( 10 ) 頁： 963-968   2014年

最新がん薬物療法学　小細胞肺癌 招待有り

森瀬昌宏, 後藤功一

日本臨床 増刊号   72 巻 ( 2 ) 頁： 346-349   2014年

Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System 査読有り

Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y

Mol Clin Oncol   2 巻 ( 6 ) 頁： 991-996   2014年

Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer 査読有り

Morise M, Niho S, Umemura S, Matsumoto S, Yoh K, Goto K, Ohmatsu H, Ohe Y

Jpn J Clin Oncol   44 巻 ( 9 ) 頁： 846-51   2014年

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis 査読有り

  9 巻 ( 9 ) 頁： 1324-31   2014年

講座　肺癌化学療法の最前線　小細胞肺癌に対する化学療法 招待有り

森瀬昌宏, 後藤功一

呼吸   32 巻 ( 7 ) 頁： 631-637   2013年

特集　オンコロジーエマージェンシーと支持療法の進歩　抗がん剤による過敏反応，インフュージョンリアクション 招待有り

森瀬昌宏, 後藤功一

呼吸器内科   23 巻   頁： 261-267   2013年

Nongenomic effects of fluticasone propionate and budesonide on human airway anion secretion 査読有り

Mizutani T, Morise M, Ito Y, Hibino Y, Matsuno T, Ito S, Hashimoto N, Sato M, Kondo M, Imaizumi K, Hasegawa Y

Am J Respir Cell Mol Biol   47 巻 ( 5 ) 頁： 645-51   2012年

Capsaicinoids regulate airway anion transporters through Rho kinase- and cyclic AMP-dependent mechanisms 査読有り

Hibino Y, Morise M, Ito Y, Mizutani T, Matsuno T, Ito S, Hashimoto N, Sato M, Kondo M, Imaizumi K, Hasegawa Y

Am J Respir Cell Mol Biol   45 巻 ( 4 ) 頁： 684-91   2011年

Heterologous regulation of anion transporters by menthol in human airway epithelial cells 査読有り

Morise M, Ito Y, Matsuno T, Hibino Y, Mizutani T, Ito S, Hashimoto N, Kondo M, Imaizumi K, Hasegawa Y

Eur J Pharmacol   10 巻 ( 635 ) 頁： 204-211   2010年

Dual pathway activated by tert-butyl hydroperoxide in human airway anion secretion

Matsuno T, Ito Y, Ohashi T, Morise M, Takeda N, Shimokata K, Imaizumi K, Kume H, Hasegawa Y

J Pharmacol Exp Ther   327 巻 ( 2 ) 頁： 453-64   2008年

肺病変を伴ったmulticentiric Castleman’s diseaseの一例 査読有り

森瀬昌宏, 下元博史, 本多 豊大, 森 良雄

日本呼吸器学会誌   41 巻   頁： 59-65   2003年

胸壁原発悪性線維性組織球腫の1例 査読有り

下元博史, 森瀬昌宏, 佐藤榮作, 山内晶司

日本胸部臨床   62 巻 ( 6 ) 頁： 561 -566   2003年

レジメン別看護速習覚え書き　肺癌

森瀬昌宏, 大江裕一郎（ 担当： 共著）

メディカ出版  2012年 

症例から学ぶメディカルオンコロジー　局所進行非小細胞肺癌症例

森瀬昌宏、長谷川好規（ 担当： 単著）

医薬ジャーナル社  2011年10月 

コリンズスターン　胸部画像診断エッセンシャル　9章　胸膜、胸壁、横隔膜　訳

森瀬昌宏, 下方智也（ 担当： 共著）

西村書店  2011年4月 

The indication of primary prevention for febrile neutropenia (FN) in elderly NSCLC patients treated with docetaxel. 国際会議

Morise M, Kondo M, Hasegawa Y.

2016 the Japanese Society of Medical Oncology Annual Meeting 

The efficacy and safety of re-challenge platinum plus pemtrexed combination therapy for recurrent malignant pleural mesothelioma 国際会議

Mariko Morishita, Masahiro Morise, Tetsunari Hase, Mitsuo Sato, Masashi Kondoh, Yoshinori Hasegawa.

16th World Conference on Lung Cancer 

Clinicopathological analysis of SRE in patients with SCLC and NSCLC 国際会議

Morise M, Kondo M, Hasegawa Y

Japan Society of Medical Oncology Annual meeting 2015 

The prophylactic antiemetic treatment failure in patients with lung cancer treated with CBDCA based-chemotherapy 国際会議

Ichikawa K, Morise M, Miyazaki M, Hase T, Kondo M, Hasegawa Y, Yamada K

Japan Society of Medical Oncology Annual meeting 2015 

Can we predict serious adverse events (SAEs) and clarify unfit population for platinum-based chemotherapy in elderly patients (over 70 years of age) with advanced Non-small cell lung cancer (NSCLC)? (CJLSG 1203 trial) 国際会議

Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindo J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Kondo M, Saito H, Hasegawa Y.

European Society of Medical Oncology Annual meeting 2014 

Clinicopathological analysis of long-term (more than 2 years) progression-free survivors treated with epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR mutation-positive non-small cell lung cancer. 国際会議

Masahiro Morise, Koichi Goto, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Kanji Nagai, Yuichiro Ohe.

15th World Conference on Lung Cancer 

Final results of EGFR mutation reanalysis and KRAS mutation screening by Scorpion ARMS method: Phase II Study of Erlotinib for EGFR wild type Non-small cell Lung Cancer Patients. Central Japan Lung Study Group (CJLSG) 0903 trial. 国際会議

Eiichi Maruyama, Masahiro Morise, Tetsunari Hase, Hiroyuki Taniguchi, Hideo Saka, Joe Shindoh, Ryujiro Suzuki, Eiji Kojima, Kenji Ogawa, Takuya Ikeda, Yasuhiro Nozaki, Masahiko Ando, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa.

15th World Conference on Lung Cancer 

Phase II Study of Erlotinib for previously treated Non-small-cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation: Central Japan Lung Study Group (CJLSG) 0903 trial 国際会議

Masahiro Morise, Hiroyuki Taniguchi, Hideo Saka, Joe Shindoh, Ryujiro Suzuki, Eiji Kojima, Tetsunari Hase, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa.

高齢者非小細胞肺癌に対するプラチナ製剤併用療法に関する多施設共同後向き観察研究　（Central Japan Lung Study Group 1203試験）

田中健太郎、森瀬昌宏、安藤昌彦、加藤俊夫、小島英嗣、小笠原智彦、鈴木隆二郎、進藤丈、松本政実、杉野安輝、野﨑裕広、小川雅弘、長谷哲成、近藤征史、斉藤博、長谷川好規

第55回日本呼吸器学会学術講演会 

再発小細胞肺癌に対しアムルビシン単剤療法を施行した患者の予後因子の検討

森瀬昌宏, 麻生裕紀, 長谷哲成, 若原恵子, 伊藤理, 橋本直純, 佐藤光夫, 近藤征史, 長谷川好規

第52回日本癌治療学会総会 

EGFR-TKIにより2年以上の長期無増悪生存が得られるEGFR遺伝子変異陽性非小細胞肺癌の臨床病理学的検討

森瀬昌宏、後藤功一、梅村茂樹、松本慎吾、葉清隆、仁保誠治、大松広伸、永井完治、大江裕一郎

第54回日本肺癌学会総会 

Capsaicinoids regulate airway anion transporters through Rho kinase- and cAMP-dependent mechanisms

再発小細胞肺癌に対する60mg/m2・3週投与1週休薬法によるイリノテカン単剤療法の検討 国際会議

森瀬昌宏、仁保誠治、梅村茂樹、松本慎吾、葉清隆、後藤功一、大松広伸、大江裕一郎

第53回日本肺癌学会総会 

Prognostic Factors in Recurrent Small Cell Lung Carcinoma 国際会議

Masahiro Morise, Takefumi Mizutani, Tomoyo Oguri, Naoyuki Imai, Tetsunari Hase, Yuichiro Shindo, Yoshihiro Inukai, Satoru Ito, Naozumi Hashimoto, Mitsuo Sato, Masashi Kondo, Yoshinori Hasegawa.

Japan Society of Medical Oncology Annual meeting 

Prospective Analysis of Efficacy and Safety of Individualized Administration of Midazolam for Sedation During Bronchoscopy 国際会議

Imaizumi K, Hashimoto I, Shindo Y, Imai N, Ogawa T, Morise M, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y

CHEST 2011 

ヒト気道上皮のイオン輸送体に対するmentholの細胞骨格を介した制御 国際会議

森瀬昌宏、伊藤康、日比野佳孝、伊藤理、橋本直純、近藤征史、今泉和良、長谷川好規

アレルギー学会総会秋季大会 

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC 国際共著 国際会議

Spigel D., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z. G., Geater S., Ozguroglu M., Mocci S., McCleland M., Enquist I., Komatsubara K. M., Deng Y., Kuriki H., Wen X., Jassem J., Herbst R. S.

ANNALS OF ONCOLOGY  2019年10月 

Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC 国際共著 国際会議

Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.

ANNALS OF ONCOLOGY  2020年9月 

Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) 国際会議

Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.

JOURNAL OF THORACIC ONCOLOGY  2019年10月 

eIF2 beta, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer 国際会議

Goto D., Tanaka I., Sato M., Kato T., Miyazawa A., Hase T., Morise M., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2018年10月 

Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung 国際会議

Morise Masahiro, Hishida Tomoyuki, Takahashi Akiko, Yoshida Junji, Ohe Yuichiro, Nagai Kanji, Ishii Genichiro

JOURNAL OF THORACIC ONCOLOGY  2017年1月 

Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study 国際共著 国際会議

Herbst R. S., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D. R., Jassem J.

ANNALS OF ONCOLOGY  2019年12月 

Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 国際共著 国際会議

Herbst R. S., De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D., Jassem J.

SWISS MEDICAL WEEKLY  2020年11月18日 

Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) 国際会議

Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.

JOURNAL OF THORACIC ONCOLOGY  2019年10月 

Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC 国際共著 国際会議

Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.

ANNALS OF ONCOLOGY  2020年9月 

A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan) 国際会議

Daga Haruko, Umemura Shigeki, Ohe Yuichiro, Shiota Tetsuhiro, Fujita Masaki, Furuya Naoki, Tsuda Takeshi, Morise Masahiro, Matsumoto Shingo, Goto Koichi

ANNALS OF ONCOLOGY  2017年10月 

Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC). 国際会議

Seto Takashi, Nishio Makoto, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Kim Young Hak, Azuma Koichi, Takiguchi Yuichi, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Nakagawa Kazuhiko, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Tamura Tomohide

JOURNAL OF CLINICAL ONCOLOGY  2019年5月20日 

Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer 国際会議

Oi H., Yamano Y., Yokoyama T., Matsuda T., Morise M., Kataoka K., Kimura T., Kondoh Y.

ANNALS OF ONCOLOGY  2019年11月 

UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer 国際会議

Goto D., Kizuki M., Uwatoko N., Kawai K., Koike M., Nakashima M., Miyazawa A., Tanaka I., Hase T., Morise M., Hasegawa Y., Minna J., Sato M.

JOURNAL OF THORACIC ONCOLOGY  2019年10月 

The Subunit eIF2 ss of Translation- Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer 国際会議

Sato Mitsuo, Tanaka Ichidai, Goto Daiki, Kato Toshio, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Kondo Masashi, Hasegawa Yoshinori

CANCER SCIENCE  2018年12月 

Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A 国際共著 国際会議

Mazieres J., Paik P., Felip E., Veillon R., Sakai H., Cortot A., Viteri S., Garassino M., Van Meerbeeck J., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.

JOURNAL OF THORACIC ONCOLOGY  2021年1月 

Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data 国際共著 国際会議

Sakai H., Felip E., Cortot A. B., Veillon R., Griesinger F., Patel J., Horn L., Mazieres J., De Castro Carpeno J., Morise M., Sakamoto T., Bruns R., Scheele J., Straub J., Paik P.

ANNALS OF ONCOLOGY  2018年11月 

Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A 国際共著 国際会議

Mazieres J., Paik P. K., Felip E., Veillon R., Sakai H., Cortot A. B., Viteri S., Garassino M. C., Van Meerbeeck J. P., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.

ANNALS OF ONCOLOGY  2020年9月 

Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study 国際共著 国際会議

Sakai Hiroshi, Veillon Remi, Cortot Alexis B., Felip Enriqueta, Mazieres Julien, Morise Masahiro, Sakamoto Tomohiro, Tokito Takaaki, Atagi Shinji, Kato Terufumi, Kumagai Toru, Tanaka Hiroshi, Bruns Rolf, Straub Josef, Scheele Juergen, Le Xiuning, Paik Paul K.

ANNALS OF ONCOLOGY  2019年10月 

Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study 国際会議

Park K., Felip E., Veillon R., Cortot A., Mazieres J., Sakai H., Reinmuth N., Viteri S., Chen Y-M., Han J-Y., Jang T-W., Morise M., Sakamoto T., Tokito T., Cho B. C., Bruns R., Scheele J., Straub J., Le X., Paik P. K.

ANNALS OF ONCOLOGY  2019年11月 

Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping 国際共著 国際会議

Yang J. C-H., Le X., Cho B. C., Han J-Y., Morise M., Chen Y-M., Kang J-H., Kato T., Takeoka H., Chikamori K., Sakai H., Park K., Wu Y-L., Schumacher K., Bruns R., Straub J., Paik P.

ANNALS OF ONCOLOGY  2020年11月 

Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC 国際共著 国際会議

Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M., Stanton T., Morise M., Lee J. -S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P.

JOURNAL OF THORACIC ONCOLOGY  2021年1月 

Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy 国際会議

Hase T., Miyazaki M., Ichikawa K., Yogo N., Ozawa N., Ando M., Morise M., Sato M., Kondo M., Yamada K., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2018年10月 

Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC 国際会議

Matsuzawa R., Morise M., Tanaka I., Koyama J., Kimura T., Kondoh Y., Hase T., Sakamoto K., Hashimoto N., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2019年10月 

Risk Factor Evaluation of Programmed Death 1 Inhibitor Related Pneumonitis in Patients with Non-Small Cell Lung Cancer 国際会議

Fukihara J., Sakamoto K., Iwano S., Morise M., Hashimoto N., Hasegawa Y.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  2018年 

PREDICT1: An observational study for identifying blood biomarkers associated with clinical benefit from carboplatin and pemetrexed (CbP) treatment in patients with non-squamous (NS) non-small cell lung cancer (NSCLC) (CJLSG1201). 国際会議

Hase Tetsunari, Yanagisawa Kiyoshi, Fukatsu Asuki, Kimura Tomoki, Kojima Eiji, Abe Takashi, Imaizumi Kazuyoshi, Horio Yoshitsugu, Oguri Tetsuya, Yamamoto Masashi, Ogasawara Tomohiko, Sugino Yasuteru, Morise Masahiro, Nakatochi Masahiro, Ando Masahiko, Kondo Masashi, Saka Hideo, Saito Hiroshi, Hasegawa Yoshinori, Takahashi Takashi

JOURNAL OF CLINICAL ONCOLOGY  2020年5月20日 

Phase II study of tepotinib in NSCLC patients with METex14 mutations. 国際共著 国際会議

Paik Paul K., Veillon Remi, Cortot Alexis B., Felip Enriqueta, Sakai Hiroshi, Mazieres Julien, Griesinger Frank, Horn Leora, Senellart Helene, Van Meerbeeck Jan P., de Castro Carpeno Javier, Patel Jyoti D., Garassino Marina Chiara, Morise Masahiro, Reinmuth Niels, Viteri Santiago, Tokito Takaaki, Sakamoto Tomohiro, Scheele Juergen, Le Xiuning

JOURNAL OF CLINICAL ONCOLOGY  2019年5月20日 

Phase II study of gedatolisib for small-cell lung cancer (SCLC) patients (pts) with genetic alterations in PI3K/AKT/mTOR pathway based on a large-scale nationwide genomic screening network in Japan (EAGLE-PAT/LC-SCRUM-Japan). 国際会議

Udagawa Hibiki, Ikeda Takaya, Umemura Shigeki, Daga Haruko, Toyozawa Ryo, Harada Daijiro, Sakakibara-Konishi Jun, Morise Masahiro, Yamamoto Noboru, Takahashi Toshiaki, Kato Terufumi, Shingyoji Masato, Ushio Ryota, Hara Satoshi, Takata Saori, Nomura Shogo, Matsumoto Shingo, Niho Seiji, Sato Akihiro, Goto Koichi

JOURNAL OF CLINICAL ONCOLOGY  2020年5月20日 

Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study 国際会議

Shimokawa M., Nosaki K., Seto T., Ohashi K., Morise M., Fujiwara Y., Sakakibara J., Murakami H., Yano S., Satouchi M., Matsumoto S., Goto K., Yoh K.

ANNALS OF ONCOLOGY  2019年4月 

IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC 国際共著 国際会議

Herbst Roy, De Marinis Filippo, Giaccone Giuseppe, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos, Morise Masahiro, Font Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Mocci Simonetta, McCleland Mark, Enquist Ida, Komatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Spigel David

JOURNAL FOR IMMUNOTHERAPY OF CANCER  2020年4月 

Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC 国際共著 国際会議

Reinmuth Niels, Spigel David, De Marinis Filippo, Giaccone Giuseppe, Verynenegre Alain, Barrios Carlos Henrique, Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozgueroglur Mustafa, Mocci Simonetta, Mccleland Mark, Enquist Ida, Kotnatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Herbst Roy S.

ONCOLOGY RESEARCH AND TREATMENT  2020年2月 

Impact Of Mild To Moderate COPD On Prognosis And Feasibility For Chemotherapy In Patients With Lung Cancer

Omote N., Hashimoto N., Morise M., Miyazaki S., Ando A., Hasegawa Y.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  2017年 

Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT 国際会議

Tamiya Y., Morise M., Matsuzawa R., Tanaka I., Okada T., Iwano S., Hase T., Hashimoto N., Sato M., Itoh Y., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2019年10月 

Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status 国際会議

Koyama Junji, Kimura Tomoki, Oi Hajime, Yamano Yasuhiko, Yokoyama Toshiki, Matsuda Toshiaki, Kataoka Kensuke, Matsuzawa Reiko, Fukihara Jun, Sakamoto Koji, Morise Masahiro, Hashimoto Naozumi, Kondoh Yasuhiro, Hasegawa Yoshinori

ANNALS OF ONCOLOGY  2019年10月 

Identification of Proteosomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen 国際会議

Sato M., Kakumu T., Goto D., Kato T., Yogo N., Hase T., Morise M., Fukui T., Yokoi K., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

JOURNAL OF THORACIC ONCOLOGY  2017年11月 

次世代シークエンサーによる網羅的がん関連遺伝子パネル解析を用いたHER2遺伝子変異陽性の進行非小細胞肺癌に対する治療開発を目指した研究 (AMED)

2018年 - 2019年

革新的がん医療実用化研究事業  

岡本勇

悪性胸膜中皮腫に対する血管新生阻害剤の効果予測モデル構築に基づく新治療法確立に関する研究 (AMED)

2017年9月 - 2018年3月

革新的がん医療実用化研究事業 

長谷川好規

遺伝子スクリーニング基盤（LC-SCRUM-Japan）を利用した、MET遺伝子異常陽性の進行非小細胞肺癌に対する治療開発を目指した研究 (AMED)

2017年4月 - 2020年3月

革新的がん医療実用化研究事業  

非小細胞肺癌に対するクリゾチニブ治療の予防制吐を目的とした経口グラニセトロン、デキサメサゾン併用療法の有効性・安全性を検討する第II相試験 （多施設共同介入研究）(Primary Investigator; Koichi Goto, M.D., Ph.D., Co- investigator; Masahiro Morise, M.D., Ph.D.)

2015年1月 - 現在

国内共同研究